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able morbidity and mortality after allogeneic hematopoietic
stem cell transplantation (HCT). Other than lung trans-
plantation (LT), no speciﬁc therapies exist for end-stage lung
disease resulting from HCT-related complications such as
bronchiolitis obliterans syndrome. Here we describe the
indications and outcomes in patients who had LT after HCT
for hematologic disease.
Methods: Retrospective chart review of cases identiﬁed by
the Long-Term Follow Up (LTFU) database at the Fred
Hutchinson Cancer Research Center/Seattle Cancer Care
Alliance. This database captures information provided by
patients, primary physicians and by LTFU clinical service via
telemedicine or by medical evaluation on site. Any patient
who received a HCT at our institutionwith a reported history
of LT was included.
Results: We identiﬁed 9 recipients of allogeneic HCT
between 1971 and 2006 who subsequently received LT
between 1990 and 2010. The median age at the time of HCT
was 16 (range, 10-35) years, and the median age at the time
of LT was 34 (range, 17-44) years. The diagnosis at the time of
HCT was acute leukemia (n¼7), chronic myeloid leukemia
(n¼1) and aplastic anemia (n¼1). The median interval
between HCT and LT was 123 (range, 35-326) months. None
of the patients had evidence of the original hematologic
disorder at time of LT. Indications for LT included pulmonary
ﬁbrosis related to any history of radiation or chemotherapy
before or as part of the conditioning regimen for HCT (n¼4),
interstitial pneumonitis related to graft-versus-host-disease
(n¼1), bronchiolitis obliterans syndrome (n¼3), and primary
pulmonary hypertension (n¼1). All patients received
unilateral (n¼4) or bilateral cadaveric LT (n¼5). Survival at
one and ﬁve years after LT was 89% and 37%, respectively.
Eight of the 9 patients died at a median of 49 months (range,
2 weeks to 87 months), and 1 is alive more than two years
after LT. Deaths were attributed to chronic graft rejection
and/or pulmonary infectious complications in 6 patients and
anoxic brain injury from cardiac and pulmonary arrest in 1
patient. Information about the cause of death for 1 patient
who died 2 weeks after LT was unavailable. According to
a nationwide registry of organ transplantation (2010 OPTN/
STRT Annual Data Report), survival of all LT recipients at one
year improved from 72% in 1990 to 85% in 2008; survival at
ﬁve years improved from 39% in 1990 to 56% in 2004.
Conclusions: LT can prolong survival in some adult and
adolescent patients who suffer from end-stage pulmonary
complications after HCT. These results can help to inform
HCT patients who are considering LT. HCT patients with
progressive pulmonary disease, but otherwise in good
health, should be referred to an established LT center for
evaluation, since early identiﬁcation of good candidates for
LT may result in better survival outcomes.201
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HSCT is a clinical procedure that involves lethal risk.
However, it sometimes arises as the only possibility for
survival. Patients ﬁnd a multiplicity of side effects resultingfrom the illness and its treatment. Graft versus host disease
(GVHD) is one of themost important causes ofmorbidity after
HSCT. We designed this study in order to evaluate the impact
of graft versus host disease on QoL healtth, sexuality and
fatigue in long term survivors after HSCT. This is a prospective
seccional study of 214 long term survivors after HSCT, which
were divided in two groups for comparison: Group 1 (G1¼89)
survivors with GVHD e Group 2 (G2¼125) without GVHD. G1
was further divided into three groups according to GVHD
classiﬁcation: Group a (Ga) e acute GVHD; Group c (Gc) e
chronic GVHD; Grupo ac (Gac) acute and chronic GVHD. Level
of satisfaction about QoL, sexuality, health and fatigue were
evaluated. All patients had at least 18 years old. Scales used
were: WHOQOL, Functional Assessment of Cancer Therapy:
Fatigue FACT-F, Karnofsky Performance Status Scale and
Socioeconomic demographic survey. Level of signiﬁcance in
all scales was 95% (p  0.05) for all risk factors for QoL.
Among survivors from groups G1 and G2, there were
more males (61.8% and 67%), married (63% 54.8%), and low
socio economic status (67.4% and 61.3) patients. Both groups
had similar percentage of survivors with more than eight
years of scholarship (67%). Median age of survivor from G1
was 3910 years and from G2, 329.6 years.
Most of G1 survivors (67.4%) were 25.9 10.8 years old at
the time of transplant versus 19.510 years old for G2.
Malignant diseases were predominant at G1 (60.7%) when
compared to G2 (29.8%). At the time of the study, 73% of
survivors from G1 and 82% from G2 had 10 to 15 years after
HSCT. Pre and post HSCT Karnofsky scores were similar for
both groups: G1 (89.9% e 98.9%), G2 (83.9% e 99.2%). Survi-
vors from both groups reported satisfactionwith QoL, health,
and sexuality. 65.2% from G1 and 75.4% from G2 reported
absence of fatigue. These results show that level of satisfac-
tion of long term survivors with their QoL, health, sexuality
and fatigue were favorable in spite of having been diagnosed
with acute or chronic graft-versus-host-disease. Trans-
plantation provides an opportunity for changes in subjec-
tivity and in facing life's adversities. It is therefore crucial that
the QOL assessment can be part of the clinical protocol, once
it provides information about risk factor which allow for the
best choice of interventions.202
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Introduction: Many recipients of allogeneic haemopoietic
stem cell transplant (HSCT) & families need ongoing clinical,
psychological & rehabilitative information & support post-
transplant. Optimisation of internet resources may ensure
easy access to relevant & accurate information. The aims of
this three phase project were to (1) assess the psychosocial
needs & (2) evaluate the impact of a speciﬁcally designed
website (Allograft Information Exchange: ALLINEX) as an
adjunct to standard care post-HSCT.
Methods: The project was approved by the regional research
ethics committee.
Phase one: Assessment of post-transplant standard care
(SC) was achieved by 1) cross-sectional patient interview
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service evaluation in 3 regional HSCTcentres (84 participants
in 8 professional groups).
Phase two:ALLINEX development & beta testing. Web-site
content was designed by health & psychosocial care
specialists in response to the outcomes of Phase I. Local &
national information resources were used to provide
content. Beta testing in patients (23), HSCT staff (24) & family
doctors (3) drove iterative development culminating in
a ﬁnal design for use in phase three.
Phase three: A randomised pilot study recruited patients
<2.5y post-HSCT with predicted minimum review of 2 clinic
visits within 12 weeks of informed consent. Stratiﬁed ran-
domisation (with/without Graft versus Host Disease) allo-
cated participants to SC or SC plus ALLINEX. Patient reported
outcomes including HADS, SDI-21 & EORTC QLQ-C30 were
collected at baseline & 12w post consent. Patients in the
intervention arm completed questionnaires on Patient
Acceptance & Use of Technology at 6w, ALLINEX feedback &
system usability scale at 12w & had website activity tracked.
All clinic visits were audio-recorded for simple content
analysis & additional contacts logged.
Results: Services evaluation identiﬁed gaps in service (e.g.
limited psychological support), standard services (e.g. open
access to transplant team) & reactive services (e.g.referrals to
psychiatry). Consequently, ALLINEX included information in
5 domains ranging from “everyday living” to “end of life,” an
interactive patient forum & a messaging system for con-
tacting the HSCT team. Beta testing resulted in minor
amendments.
Phase three recruitment was completed September 2012
with a participation rate of 71% & 50/53 patients completing
the study. Analysis is ongoing (due completion December
2012).
Conclusions: Involvement of patients & staff at all stages of
ALLINEX development has resulted in a website that per-
formed well in preliminary testing. Initial analysis indicates
that the site is relevant, accessible & comprehensive. Final
analysis may lead to changes in ALLINEX, guidance training
for patients & staff & further development of the interactive
aspects of the site.
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Measure Name Purpose Domains
Functional Assessment of Cancer
Therapy, Bone Marrow
Transplant (FACT- BMT)
HSCT patients
speciﬁc QOL
Physical, social, fun
emotional wellbein
BMT symptom sca
total score
European Organization for the
Research and Treatment of
Cancer Quality of Life
Questionnaire Cancer (EROTC)
General Measure
QOL in cancer
Physical, social, rol
emotional, Sympto
fatigue, pain, naus
Global health/QOL
Domain and Total
Medical Outcome Study SF-36 General Measure in
QOL in healthy and
medicine populations
Physical functionin
bodily pain, genera
social functioning,
mental health com
physical and mentUniverstiy Medical Center, Durham, NC; 3Medicine/Oncology,
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Objective: Hematopoietic stem cell transplantation (HSCT) is
a potentially curative therapy for malignant and autoim-
mune diseases. As the scope of transplant expands treatment
for more diseases and patient types, quality of life (QOL)
speciﬁcally fatigue, will remain an important measure for
outcome and long term survival in HSCT. Overall QOL is re-
ported to return to baseline or exceeds baseline by one year
while fatigue remains amajor symptom that is long lasting as
far out as 10 years.
Methods: A Pub Med search was completed in 2009 using
mesh terms, HSCT, bone marrow transplant, and quality of
life. This resulted in one hundred and seventy nine articles.
When fatigue was added to the mesh terms the number of
articles dropped to eleven. Highly relevant references were
chosen from articles and books. The National Comprehensive
Cancer Network (NCCN)websitewas also used as a source for
cancer related fatigue.
Results: Long term follow up studies of HSCT patients as far
out as ten years report fatigue as high as 35%. In comparative
trials with healthy controls this has been shown to be
statistically signiﬁcant. Multiple reasons may exist for this
prolonged decrement including chronic graft versus host
disease, preparative regimens, treatment prior to HSCT and
underlying disease. No studies to date have determined the
underlying etiology of long standing fatigue. Small studies
with exercise interventions and cognitive behavioral therapy
show promising results. These types of treatment may have
an impact on patients with fatigue following HSCT.
Conclusion: Multidimensional scales have been used to
measure fatigue in many QOL studies but few to date have
used fatigue speciﬁc scales. Multimodal interventions have
been shown to decrease the loss of aerobic ﬁtness, muscle
strength, and functional performance. Interventions with
exercise in addition to behavioral therapy with objective
physical measures and fatigue measurement scales may be
beneﬁcial in determining the cause of this chronic symptom
in patients post HSCT.
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